Artivion's stock plummeted 31.11% in after-hours trading on Thursday, following the release of its first-quarter financial results.

The cardiac device maker reported Q1 revenue of $116.3 million, an 18% year-over-year increase that slightly beat analyst expectations. Adjusted earnings per share came in at $0.08, also surpassing estimates. However, investor sentiment turned sharply negative as the company revised its full-year 2026 guidance downward.

Artivion lowered its revenue outlook to a range of $480 million to $496 million, from a previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA guidance to $100 million to $107 million. Management indicated that U.S. revenue from the recently FDA-approved NEXUS Aortic Arch System is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious outlook.